June 19, 2020 0 Comments

Aún no se establecióel lugar que ocupa la anticoagulación en el tratamiento . y coagulación La dosis profiláctica de este agente se comparó con placebo. Alternativas: vigilancia con US para detectar progresión a VA, anticoagulación en dosis profiláctica, anticoagulación en dosis terapéutica por menos de 3 meses. Tras la anticoagulación, se observan complicaciones hemorrágicas mayores en el . guía de actuación profiláctica y de tratamiento para este tipo de pacientes.

Author: Malazragore Gugar
Country: Belarus
Language: English (Spanish)
Genre: Photos
Published (Last): 15 April 2009
Pages: 438
PDF File Size: 12.86 Mb
ePub File Size: 18.18 Mb
ISBN: 241-7-49430-771-1
Downloads: 29144
Price: Free* [*Free Regsitration Required]
Uploader: JoJoramar

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name. Pneumonia AND sponsor name.

anticoaghlacion How to search [pdf]. For these items you should use the filters and not add them to your search terms in the text field.

Enfermedad tromboembólica venosa y cirrosis hepática

Trials with results Trials without results Clear advanced search filters. Review by the Competent Authority or Ethics Committee in the country concerned.


EU Clinical Trials Register. Both Female Only Male Only. IMP with orphan designation in the indication. Trials with results Trials without results. Clear advanced search filters.

Date on which this record was first entered in the EudraCT database:. Randomized controlled trial on the safety and efficacy of low molecular weight heparins in the prevention of thrombotic events in hospitalized cirrhotic patients.

Clinical Trials Register

Title of the trial for lay people, in easily understood, i. Trial about the prevention of thrombosis in hospitalized cirrhotic patients.

The IMP has been ajticoagulacion in this indication as an orphan drug in the Community. Committee on Advanced anticoavulacion CAT has issued a classification for this product. Combination product that includes a device, but does not involve an Advanced Therapy.

Prevention of thrombosis in cirrhotic patients. To assess the safety and efficacy of prophylactic anticoagulation for the prevention of thrombotic events in hospitalized cirrhotic patients. To assess prospectively the incidence of thrombotic events in hospitalized cirrhotic patients. To Identify risk factors for development of portal vein thrombosis and deep vein thrombosis in hospitalized patients.


To evaluate related morbidity and mortality thromboembolic events. Identificar factores de riesgo de desarrollo de trombosis portal y trombosis venosa profunda en pacientes hospitalizados.

Clinical trials

Applicants must meet all the following: One or more of the antifoagulacion Related peripheral and portal thrombosis. The trial involves single site in the Member State concerned.

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.